Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine

CNS Drug Reviews

Volumn 12, Issue 3-4, 2006, Pages 208-217

  Hofmann, Stefan G ^a   Pollack, Mark H ^b   Otto, Michael W ^a  

^a BOSTON UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anxiety disorders; Augmentation therapy; D cycloserine; Extinction learning; Memory enhancement; NMDA receptor agonists

Indexed keywords

CYCLOSERINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

ADD ON THERAPY; AMYGDALOID NUCLEUS; ANXIETY DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG INDICATION; EXPOSURE; HEADACHE; HUMAN; LEARNING; LONG TERM POTENTIATION; MEMORY; MEMORY DISORDER; NEGATIVE SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; PARESTHESIA; PHOBIA; PSYCHOTHERAPY; RATING SCALE; REVIEW; SEIZURE; SOCIAL PHOBIA; TREATMENT OUTCOME; TREMOR; TUBERCULOSIS; VERTIGO;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CYCLOSERINE; HUMANS; PSYCHOTHERAPY;

EID: 33845972285     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2006.00208.x     Document Type: Review

References (69)

1. th edition. Washington: American Psychiatric Association, 1994;1-886.
2. Blair HT, Tinkelman A, Moita MA LeDoux JE. Associative plasticity in neurons of the lateral amygdala during auditory fear conditioning. Ann NY Acad Sci 2003;985:485-487.
3. Bliss TV, Collingridge GL. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993;361:31-39.
4. Boje KM, Wong G, Skolnick P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res 1993;603:207-214.
5. Bouton ME. Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction. Biol Psychiatry 2002;52:976-986.
6. Cahill L, Weinberger NM, Roozendaal B, McGaugh JL. Is the amygdala a locus of "conditioned fear"? Some questions and caveats. Neuron 1999;23:227-228.
7. Collinridge GL, Kehl SJ, McLennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J Physiol 1983;224:22-46.
8. Davis M, Meyers KM, Ressler KJ, Rothbaum BO. Facilitation of extinction of conditione fear by D-cycloserine. Curr Dir Psychol Sci 2005;14:214-219.
9. Davis M, Walker DL, Meyers KM. Role of the amygdala in fear extinction measured with potentiated startle. Ann NY Acad Sci 2003;985:218-232.
10. Duncan EJ, Szilagyi S, Schwartz MP, et al. Effects of D-cycloserine on negative symptoms of schizophrenia. Schizophr Res 2004;71:239-248.
11. D'Souza DC, Gil R, Cassello K, et al. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry 2000;47:450-462.
12. Fakouhi TD, Jjee SS, Sramek JJ, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol 1995;8:226-230.
13. Falls WA, Miserendino MJD, Davis M. Extinction of fear-potentiated startle: Blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci 1992;12:854-863.
14. Fanselow MS, LeDoux JE. Why we think plasticity underlying Pavlovian fear conditioning occurs in the basolateral amygdale. Neuron 1999;23:229-232.
15. Foa EB, Franklin ME, Moser J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry 2002;10:987-997
16. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-1377.
17. Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 2005;179:144-150.
18. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999;56:21-27.
19. Golden RN. Making advances where it matters: Improving outcomes in mood and anxiety disorders. CNS Spectr 2004;9:14-22.
20. Guastella AJ, Dadds MR, Lovibond PF, Mithcell P, Richardson G. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res; In press.
21. Guastella AJ, Lovibon P, Dadds MR, Mitchell P. A randomized controlled trial of the effect of D-cycloserine on extinction and fear-conditioning in humans. Behav Res Ther; In press.
22. Guy W. ECDEU assessment manual for psychopharmacology: Publication ADM 76-338. Washington: US Department of Health, Education and Welfare 1976;217-222.
23. Hebb DO. The organization of behavior. New York: Wiley, 1949;1-535.
24. Hofmann SG, Meuret AE, Smith JA, et al. Augmentation of exposure therapy for social anxiety disorder with D-Cycloserine. Arch Gen Psychiatry 2006;63:298-304.
25. Jahr CE, Stevens CF. Calcium permeability of the N-methyl-D-aspartate receptor channel in hippocampal neurons in culture. Proc Natl Acad Sci USA 1993;90:11573-1577.
26. Kessler RC, McGonagle KA, Shanyang Z, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19.
27. Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev 2002;2: CD003153.
28. Land C, Riccio DC. D-Cycloserine: Effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiol Learn Mem 1999;72:158-168.
29. Lao J, Wang Y, Yasuda RP, Dunah AW, Wolfe BB. The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B). Mol Pharmacol 1997;51:79-86.
30. Laube B, Kuhse H, Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 1998;18:2954-2961.
31. Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of conditioned fear as assessed by freezing in rats. Behav Neurosci 2003;117:341-349.
32. Ledgerwood L, Richardson R, Cranney J. D-cycloserine and the facilitation of conditioned fear: Consequences for reinstatement. Behav Neurosci 2004;118:505-513.
33. Lee HJ, Choi JS, Brown TH, Kim JJ. Amygdalar NMDA receptors are critical for the expression of multiple conditioned fear responses. J Neurosci 2000;21:4116-4124.
34. Lelong V, Dauphin F, Boulouard M. RS 67333 and D-cycloserine accelerates learning acquisition in the rat. Neuropharmacology 2001;41:517-522.
35. Li XF, Phillips R, LeDoux JE. NMDA and non-NMDA receptors contribute to synaptic transmission between the medial geniculate body and the lateral nucleus of the amygdala. Exp Brain Res 1995;105:87-100.
36. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-173.
37. Lisman J. A mechanism for the Hebb and the anti-Hebb processes underlying learning and memory. Proc Natl Acad Sci USA 1989;86:9574-9578.
38. Liu L, Wong TP, Pozzza MF, et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic placticity. Science 2004;304:1021-1024.
39. Lynch G, Larson J, Kelso S, Barrionuevo G, Schottler F. Intracellular injections in EGTA block induction of hippocampal long-term potentiation. Nature 1983;305:719-721.
40. MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Baker JL. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 1986;321:519-522.
41. Malenka RC, Nicoll RA. Long-term potentiation - a decade of progress? Science 1999;285:1870-1874.
42. Myers KM, Davis M. Behavioral and neural analysis of extinction: A review. Neuron 2002;36:567-584.
43. Nair KGS, Epstein IG, Baron H, Mulinos MG. Absorption, distribution and excretion of cycloserine in man. Antibiot Annals; 1956;3:136-140.
44. 2+ stores regulate the polarity and input specificity of synaptic medication. Nature 2000;408:584-588.
45. Nowak L, Bregestovski P, Ascher P, Herbert A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurons. Nature 1984;307:462-465.
46. Orr SP, Metzger LJ, Lasko NB, Macklin ML, Peri T, Pitman RK. De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. J Abnorm Psychol 2000;109:290-298.
47. Öst LG. One-session group treatment of spider phobia. Behav Res Ther 1996;34:707-715.
48. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis. Clin Psychol (New York) 2005;12:72-86.
49. Otto MW, Basden S, Leyro TM, McHugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and CBT for the treatment of anxiety disorders. Submitted to CNS Spectrum.
50. Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005;83:224-231.
51. th Edition. Montvale, NJ: Medical Economics Co., 2004.
52. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004;161:2115-2117.
53. Pussinen R, Sirvio J. Effects of D-cycloseiine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. J Psychopharmacol 1999;13:171-179.
54. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 1994;157:7-12.
55. Randolph C, Roberts JW, Tierney MC, Bravi D, Mourandian MM, Chase TN. D-cycloserine treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 1994;8:198-205.
56. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004;61:1136-1144.
57. Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: Theoretical and clinical implications. Learn Mem 2004;11:510-516.
58. Richter-Levin G. The amygdala, the hippocampus, and emotional modulation of memory. Neuroscientist 2004;10:31-39.
59. Rodrigues SM, Schafe GE, LeDoux JE. Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning. J Neurosci 2001;21:6889-6896.
60. Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 2005;30:633-639.
61. Santini E, Muller RU, Quirk GJ. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci 2001;21:9009-9017.
62. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. D-Cycloserine enhances implicit memory in Alzheimer patients. Neurology 1996;46:420-424.
63. Tsai G, Falk W, Gunther J, Coyle J. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry 1999;156:467-469.
64. Turner SM, Beidel DC, Dancu CV, Stanley MA. An empirically derived inventory to measure social fears and anxiety: The Social Phobia and Anxiety Inventory. J Consult Clin Psychol 1989;1:35-40.
65. Van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996;40:1298-1300.
66. Walker DL, Davis M. The role of amygdala glutamate receptors in fear learning, potentiated startle, and extinction. Pharmacol Biochem Behav 2002;71:379-392.
67. Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002;22:2343-2351.
68. Yurgelun-Todd DA, Coyle JT, et al. Functional magnetic resonance imaging studies of schizophrenic patients during word production: Effects of D-cycloserine. Psychiatry Res 2005;138:23-31.
69. Zhu M, Nix DE, Adam RDM, Peloquin CA. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 2001;21:891-897.